By optimizing the molecular structure of the low k films that insulate the miles of wiring, or interconnects, on each chip, the Producer Onyx system enables customers to continue their relentless drive to fabricate faster, more power-efficient logic devices as they scale to 22nm and below.
Fraunhofer ISE announced that it has signed an agreement to continue its collaboration on the development and production of multi-junction solar photovoltaic cells with AZUR SPACE Solar Power GmbH for another 20 years.
Applied Materials, Inc., the global leader in providing equipment to enable the manufacture of advanced semiconductor devices, has joined the Science Foundation Ireland-funded Strategic Research Cluster FORME (Functional Oxides and Related Materials for Electronics).
Aurrion, Inc., a world leader in silicon photonics, announced that is has been awarded a $13.9 million Defense Advanced Research Projects Agency (DARPA) multi-year R+D contract through the Electronic-Photonic Heterogeneous Integration (E-PHI) program.
Leonardo Biosystems, Inc. and NanoMedical Systems, Inc. (NMS), two emerging drug delivery companies, today announced that they have signed a development contract in which NMS will develop and establish a commercial process to manufacture nanoporous silicon particles for Leonardo's multi-stage drug delivery system.
The Institute of Microelectronics (IME), a research institute of the Agency for Science, Technology and Research (A*STAR), has announced plans to commercialize key innovations in silicon chips designed to support high speed, high bandwidth optical communications. These chips were developed as part of IME's Silicon Photonics research platform.
In recognition of the significant growth opportunity associated with the global battery marketplace, BASF is creating a new global business unit that will bring together its current and future battery-related electromobility activities.
This new facility provides Innovative Solutions Bulgaria, manufacturer of the BudgetSensors line of AFM probes and AFM calibration standards, with the much needed space for the expansion of its production capacity.
Selecta Biosciences, Inc., a biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacodynamic profile of SEL-068, a nicotine vaccine candidate for smoking cessation and relapse prevention.
The Ben Franklin Technology Development Authority has approved $3.15 million to be used for the University Research Commercialization Grant Program to support nanotechnology research and development activities.
mPhase Technologies, Inc. has developed a technology that exploits the phenomenon of electrowetting or the ability to electronically manipulate the way liquids behave when in contact with a solid or porous surface.